2-Picolinic Acid

2-Picolinic Acid

SCHEMBL524041

O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.[Cu+2]

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.64
CES1 P23141 1/20 0.64
L3MBTL1 Q9Y468 3/20 0.61
LMNA P02545 3/20 0.61
P4HTM Q9NXG6 2/20 0.61
NAPRT Q6XQN6 1/20 0.61
ALDH1A1 P00352 2/20 0.59
KMT2A Q03164 1/20 0.55
GSK3B P49841 1/20 0.53
KDM4E B2RXH2 4/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Picolinic Acid SCHEMBL31214632 1.00 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL11378795 0.98 CES2 (0.67) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL6054281 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL2483447 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL15401421 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL5354659 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL432467 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL673572 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL5058098 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL11378797 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025029611-A1 THERAPIES FOR DISEASES OF COPPER METABOLISM THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2025-02-06 WO claimed
EP-4187558-B1 APPLICATION OF AN ADDITIVE IN A PREPARATION METHOD OF A SAMARIUM-COBALT 2:17 TYPE MAGNET FUJIAN CHANGTING ZORR TECH CO LTD (CN) 2024-07-24 EP claimed
EP-4375325-A2 BIOCIDAL RESIN COMPOSITION INCLUDING ONE OR A PLURALITY OF RESINS SELECTED FROM MF, UF, PF, MUF AND PHENOLIC RESINS; AND MORE THAN ONE SOLUBLE COPPER SALT COPPTECH UK LTD. (CL) 2024-05-29 EP claimed
US-20240075043-A1 IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS FOR WEIGHT LOSS Red Mountain Med Spa, LLC (US) 2024-03-07 US claimed
EP-4187558-A1 ADDITIVE AND APPLICATION THEREOF, AND SAMARIUM-COBALT 2: 17 TYPE MAGNET AND PREPARATION METHOD THEREOF Fujian Changting Zorr Technology Co., Ltd. (CN) 2023-05-31 EP claimed
US-20220249505-A1 APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF RED MOUNTAIN HOLDINGS, LLC (US) 2022-08-11 US claimed
CN-114255945-A Additive and application thereof, 2-17 type samarium-cobalt magnet and preparation method thereof 福建省长汀卓尔科技股份有限公司 2022-03-29 CN claimed
CN-113582921-A Production method of dipicolinic acid 江西鑫海高分子材料有限公司 2021-11-02 CN claimed
US-20210275536-A1 APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF RED MOUNTAIN HOLDINGS, LLC (US) 2021-09-09 US claimed
CN-110124499-B Treatment process for waste gas generated by recycling hazardous waste inorganic salt 内蒙古中泰汇金环保科技有限公司 2021-07-30 CN claimed
US-20040105894-A1 Trace Metals synergized copper nucleotides and copper glycosides for anti-aging and antiviral compositions GUPTA SHYAM K (US) 2004-06-03 US claimed
EP-1411965-A1 METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION Novactyl, Inc. (US) 2004-04-28 EP claimed
WO-2003006044-A1 METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION NOVACTYL, INC. (US) 2003-01-23 WO claimed
US-20020037908-A1 Methods and compositions for controlling protein assembly or aggregation NOVACTYL, INC. 2002-03-28 US claimed
US-6043370-A REACTING AROMATIC AMINE WITH AN AROMATIC HALIDE IN PRESENCE OF COPPER CONTAINING CATALYST IN A REACTION SOLVENT HAVING IONIZATION POTENTIAL OF FROM 8.0 TO 9.0 EV. SANKIO CHEMICAL CO., LTD. (JP) 2000-03-28 US claimed
CN-1139879-A Antimicrobial method and cosmetic composition OTSUKA PHARMA CO LTD (JP) 1997-01-08 CN claimed
EP-0728478-A1 ANTIMICROBIAL METHOD AND COSMETIC COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1996-08-28 EP claimed
EP-0488860-B1 Method for the production of polyalkoxylated aromatic compounds RHONE POULENC CHIMIE (FR) 1995-10-11 EP claimed
EP-0423010-B1 METHOD FOR THE PRODUCTION OF ALKOXYBENZALDEHYDES RHONE-POULENC CHIMIE (FR) 1993-09-29 EP claimed
US-RE33988-E Dietary supplementation with essential metal picolinates The United States of America as repesented by the Secretary of Agriculture (US) 1992-07-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037908-A1 Methods and compositions for controlling protein assembly or aggregation PSEN1, PSEN2, PRNP CES2 4028/4885CES1 4539/4885L3MBTL1 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.